Encysive up on CHMP positive opinion

ENCY gained $1.50 (35%) to $5.82 on Friday after the EMEA's CHMP issued a positive opinion for Thelin sitaxsentan for pulmonary arterial hypertension (PAH). As a result, several analysts upgraded the stock, including Oppenheimer's Cory Kasimov, who upgraded ENCY to "buy" from "neutral," and Cowen's Phil Nadeau, who upgraded the stock to "outperform" from "neutral." A final decision on the endothelin A receptor antagonist is expected within 90 days. Last week, ENCY submitted a complete response to a March FDA approvable letter for the product (see BioCentury Extra, Thursday May 25, 2006). ...